Follow The Filings

MLYS Mineralys Therapeutics

Mineralys Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by MLYS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All MLYS insider trades
  • $8.8M bought by 1 insider
  • $63.1M sold by 5 insiders outside a trading plan
  • $24.9M sold by 5 insiders under 10b5-1 plans
  1. Jon Congleton CEO
    Planned sale
    $1.9M 75,000 shares at $25.46 12% of stake
    Traded Sep 30 Filed Oct 2
    ↗
  2. Brian Taylor Slingsby Director
    Sale
    $3M 104,320 shares at $28.81 1.3% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  3. Eric Warren Chief Commercial Officer
    Planned sale
    $209K 7,438 shares at $28.12 16% of stake
    Traded Sep 21 Filed Sep 22
    ↗
  4. Daphne Karydas Director
    Planned sale
    $86K 3,000 shares at $28.58 33% of stake
    Traded Sep 15 Filed Sep 17
    ↗
  5. Eric Warren Chief Commercial Officer
    Planned sale
    $193K 7,437 shares at $25.98 16% of stake
    Traded Aug 21 Filed Aug 25
    ↗
  6. David Malcom Rodman Chief Medical Officer
    Planned sale
    $59K 2,170 shares at $27.09 4.1% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  7. Eric Warren Chief Commercial Officer
    Planned sale
    $200K 7,438 shares at $26.87 16% of stake
    Traded Jul 21 Filed Jul 23
    ↗
  8. David Malcom Rodman Chief Medical Officer
    Planned sale
    $11K 416 shares at $26.53 0.8% of stake
    Traded Jul 17 Filed Jul 20
    ↗
  9. Jon Congleton CEO
    Planned sale
    $291K 10,700 shares at $27.24 1.7% of stake
    Traded Jul 13 Filed Jul 15
    ↗
  10. David Malcom Rodman Chief Medical Officer
    Planned sale
    $557K 20,407 shares at $27.28 28% of stake
    Traded Jul 13–15 Filed Jul 15
    ↗
  11. David Malcom Rodman Chief Medical Officer
    Planned sale
    $66K 2,171 shares at $30.30 3.6% of stake
    Traded Jul 9 Filed Jul 10
    ↗
  12. Jon Congleton CEO
    Planned sale
    $2M 75,000 shares at $26.14 11% of stake
    Traded Jun 30 Filed Jun 30
    ↗
  13. Eric Warren Chief Commercial Officer
    Planned sale
    $2.7M 104,124 shares at $25.90 73% of stake
    Traded Jun 26 Filed Jun 30
    ↗
  14. David Malcom Rodman Chief Medical Officer
    Planned sale
    $350K 14,474 shares at $24.19 20% of stake
    Traded Jun 15–17 Filed Jun 17
    ↗
  15. Daphne Karydas Director
    Planned sale
    $75K 3,000 shares at $25.00 33% of stake
    Traded Jun 17 Filed Jun 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 63 option exercises, 13 stock grants, and 2 other transactions.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.